Tiejun Tang
Recently,
I came across a video on YouTube by a highly popular online commentator, Mr.
Wang, who claimed that the traditional Chinese patent medicine Angong Niuhuang
Wan has no therapeutic benefit in treating acute stroke and performs no better
than a placebo. Based on this, he concluded that this long-celebrated and
expensive remedy is completely ineffective. Could it really be true that a
classic formula used by traditional Chinese medicine (TCM) practitioners for
hundreds of years is useless? This article aims to analyze and discuss this
issue in detail.
Experimental studies have also provided insights into the mechanisms of Angong Niuhuang Wan.
More recently, researchers applied ultra-high-performance liquid chromatography coupled with quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Exactive-Orbitrap-MS) to identify chemical constituents in ANP and its serum-absorbed components. Using network pharmacology and transcriptomic analysis, they found that 169 compounds were identified in total, 13 of which were detected in serum and interacted with 91 key targets. ANP significantly reduced serum TNF-α and IL-6 levels, as well as hypothalamic COX-2 and PGE2 levels. It upregulated NRF2 and KEAP1 expression while downregulating TLR4, IL-17A, p-P65/P65, TNF-α, and NLRP3. In LPS-induced RAW264.7 cells, ANP inhibited excessive secretion of inflammatory mediators (NO, IL-6, TNF-α), suppressed iNOS and CD86 expression, and enhanced NRF2 expression, thereby demonstrating strong anti-inflammatory and antioxidant effects[5].
Discussion
Experimental studies have clearly demonstrated the multi-target mechanisms and material basis underlying the efficacy of Angong Niuhuang Wan. Why, then, do some clinical trials report conflicting results? What causes these discrepancies? And ultimately — is the medicine effective or not?
In my view, the key to evaluating the efficacy of a Chinese medicine lies in syndrome differentiation. No matter how famous or expensive a medicine is, if it is not prescribed according to the correct diagnosis (zheng), it will not be effective — and vice versa.
In TCM, stroke patients with impaired consciousness are classified under the category of Close Syndrome (闭证), which can be further divided into Heat Close syndrome and Cold Close syndrome. For heat close syndrome, depending on whether heat or phlegm predominates, and whether convulsions are present, practitioners select different formulas. The “Three Cooling and Orifice-Opening Treasures” — Angong Niuhuang Wan, Zhibao Dan, and Zixue Dan— are used for heat closed syndrome, whereas Suhexiang Wan is used for cold close syndrome.
Western medicine researchers often administer Angong Niuhuang Wan to all stroke patients with coma, without distinguishing between heat and cold syndromes — which contradicts TCM principles. Wu Jutong would never have used a randomized double-blind method to treat patients; instead, he and generations of TCM practitioners after him applied individualized treatments according to syndrome differentiation, saving countless lives in the process. The enduring use of this formula for over 200 years is itself strong evidence of its clinical value.
Therefore, evaluating Chinese medicine efficacy using Western evidence-based criteria alone is inappropriate and misleading. TCM requires its own evaluation system — one that respects syndrome differentiation and the holistic principles of Chinese medicine. Only through research designed on these foundations can we truly assess the therapeutic effects of formulas like Angong Niuhuang Wan.
- Li S. Safety and efficacy of Angong Niuhuang Pills in patients with moderate-to-severe acute ischemic stroke (ANGONG TRIAL): A randomized double-blind placebo-controlled pilot clinical trial. Chin Med J (Engl). 2025 Mar 5;138(5):579–588.
- Meng X. Effectiveness and safety of Angong Niuhuang Pill in treatment of acute stroke: A systematic review and meta-analysis. J Tradit Chin Med. 2023 Aug;43(4):650–660.
- Wang L. Angong Niuhuang Pill pretreatment alleviates cerebral ischemia-reperfusion injury by inhibiting excessive autophagy through the SIRT1-H4K16ac axis. J Ethnopharmacol. 2025 Jan 31;340:119214.
- Zhang X. A newly discovered bioactive equivalence of combinatorial components of Angong Niuhuang Pill improves ischemic stroke via the PI3K/AKT axis. J Ethnopharmacol. 2025 Mar 13;343:119453.
- Gao F. Explore the chemical components of Angong Niuhuang Pill and its potential mechanisms for fever treatment based on UHPLC-Q-Exactive Orbitrap HRMS, transcriptomics, and experiment verification. J Ethnopharmacol. 2025 Sep 5;354:120542.
No comments:
Post a Comment